A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

(2020) Caroline Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

(2019) Y J L Jansen et al.   ANNALS OF ONCOLOGY

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

(2019) Hussein Abdul-Hassan Tawbi et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.

(2019) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics

(2019) Romain-David Seban et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

(2019) Caroline Robert et al.   LANCET ONCOLOGY

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

(2019) Teofila Seremet et al.   Journal of Translational Medicine

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study

(2019) A. Rogiers et al.   SUPPORTIVE CARE IN CANCER

Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy

(2019) Amadeus Schraag et al.   EUROPEAN JOURNAL OF RADIOLOGY

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab

(2018) Richard W. Joseph et al.   CLINICAL CANCER RESEARCH

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

(2018) Scott J. Rodig et al.   Science Translational Medicine

FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma

(2018) A C Tan et al.   ANNALS OF ONCOLOGY

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

(2018) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

(2018) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

21PBaseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab

(2018) G Awada et al.   ANNALS OF ONCOLOGY

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

(2018) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO)

(2016) Y. Jansen et al.   ANNALS OF ONCOLOGY

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

(2016) S Diem et al.   BRITISH JOURNAL OF CANCER

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

(2016) Benjamin Weide et al.   CLINICAL CANCER RESEARCH

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

(2016) Sarah B Goldberg et al.   LANCET ONCOLOGY

The "cancer immunogram"

(2016) C. U. Blank et al.   SCIENCE

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH